ACHV
Achieve Life Sciences Inc
7.80$
+0.0%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -20.4% | +261.5% | -7.5% | -26.0% | -19.4% | -29.2% | +115.4% | -11.7% | -19.7% | -20.8% | +475.3% | |
| – | -22.4% | +298.7% | -7.7% | -27.2% | -19.9% | -31.4% | +127.6% | -12.0% | -20.3% | -22.1% | +506.2% | |
| – | -21.8% | +327.1% | -77.8% | -35.3% | +33.4% | +2.2% | +298.5% | -38.4% | -34.5% | +34.2% | +70.8% | |
| – | -21.8% | +327.1% | -7.7% | -30.0% | -20.0% | -32.3% | +138.3% | -13.1% | -24.3% | -19.6% | +539.9% | |
| – | +33.7% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | -4.4% | -4.7% | -4.8% | -5.2% | -5.4% | -5.7% | -6.0% | -6.5% | -6.9% | -7.3% | -75.7% | |
| – | +2.6% | -1.2% | +9.4% | -26.5% | +7.2% | -3.7% | +1.1% | +6.7% | +10.0% | +10.6% | +814.6% | |
| – | +409.9% | -1.2% | -33.4% | -51.0% | -0.5% | +6.7% | +20.2% | +13.5% | -6.7% | +30.3% | +1,570.4% | |
| – | +27,318.0% | +2.8% | -48.6% | -99.8% | +150.0% | +2,174.5% | +1.2% | -0.2% | +198.1% | +49.5% | +33.0% | |
| – | -3.1% | -39.6% | +47.5% | +83.8% | +92.9% | -15.1% | -26.4% | +59.5% | -55.4% | -3.9% | -27.3% | |
| – | – | – | – | +11.6% | +0.1% | -12.0% | +0.0% | +0.2% | +28.9% | -16.7% | -20.0% | |
| – | -135.9% | – | -14.5% | -25.8% | -33.4% | -50.8% | +305.4% | -19.3% | -36.0% | -50.4% | -237.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.2% | +18.3% | +37.0% | +0.1% | +0.5% | +0.5% | +0.0% | +47.1% | +4.4% | +0.2% | +75.2% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.